thalidomide has been researched along with Retinal Diseases in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Retinal Diseases: Diseases involving the RETINA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide treatment decreases PMNL infiltration, retinal edema, VEGF, and TNF-alpha synthesis following I/R injury to the guinea pig retina." | 5.35 | The effect of thalidomide on vascular endothelial growth factor and tumor necrosis factor-alpha levels in retinal ischemia/reperfusion injury. ( Akpolat, N; Aydoğan, S; Celiker, U; Ilhan, N; Türkçüoğlu, P, 2008) |
| "Thalidomide treatment decreases PMNL infiltration, retinal edema, VEGF, and TNF-alpha synthesis following I/R injury to the guinea pig retina." | 1.35 | The effect of thalidomide on vascular endothelial growth factor and tumor necrosis factor-alpha levels in retinal ischemia/reperfusion injury. ( Akpolat, N; Aydoğan, S; Celiker, U; Ilhan, N; Türkçüoğlu, P, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, B | 1 |
| Li, PK | 1 |
| Ma, JX | 1 |
| Chen, D | 1 |
| Simon, AJ | 1 |
| Lev, A | 1 |
| Zhang, Y | 1 |
| Weiss, B | 1 |
| Rylova, A | 1 |
| Eyal, E | 1 |
| Kol, N | 1 |
| Barel, O | 1 |
| Cesarkas, K | 1 |
| Soudack, M | 1 |
| Greenberg-Kushnir, N | 1 |
| Rhodes, M | 1 |
| Wiest, DL | 1 |
| Schiby, G | 1 |
| Barshack, I | 1 |
| Katz, S | 1 |
| Pras, E | 1 |
| Poran, H | 1 |
| Reznik-Wolf, H | 1 |
| Ribakovsky, E | 1 |
| Simon, C | 1 |
| Hazou, W | 1 |
| Sidi, Y | 1 |
| Lahad, A | 1 |
| Katzir, H | 1 |
| Sagie, S | 1 |
| Aqeilan, HA | 1 |
| Glousker, G | 1 |
| Amariglio, N | 1 |
| Tzfati, Y | 1 |
| Selig, S | 1 |
| Rechavi, G | 1 |
| Somech, R | 1 |
| Aydoğan, S | 1 |
| Celiker, U | 1 |
| Türkçüoğlu, P | 1 |
| Ilhan, N | 1 |
| Akpolat, N | 1 |
| McCarty, MF | 1 |
4 other studies available for thalidomide and Retinal Diseases
| Article | Year |
|---|---|
Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage.
Topics: Angiogenesis Inhibitors; Animals; Cell Proliferation; Cells, Cultured; Corneal Neovascularization; D | 2018 |
Mutations in STN1 cause Coats plus syndrome and are associated with genomic and telomere defects.
Topics: Animals; Ataxia; Brain Neoplasms; Calcinosis; Central Nervous System Cysts; Disease Models, Animal; | 2016 |
The effect of thalidomide on vascular endothelial growth factor and tumor necrosis factor-alpha levels in retinal ischemia/reperfusion injury.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Guinea | 2008 |
Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis.
Topics: Animals; Antineoplastic Agents; Callithrix; Fish Oils; Gene Expression; Humans; Hyperplasia; Inflamm | 1997 |